Cosimo Prantera

Summary

Country: Italy

Publications

  1. ncbi request reprint A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
    Cosimo Prantera
    Department of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Inflamm Bowel Dis 11:421-7. 2005
  2. doi request reprint Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial
    Cosimo Prantera
    Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Dig Liver Dis 43:459-64. 2011
  3. doi request reprint Budesonide multi-matrix system formulation for treating ulcerative colitis
    Cosimo Prantera
    Gastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87 00152 Rome, Italy 39 6 3202643 39 6 3202643
    Expert Opin Pharmacother 15:741-3. 2014
  4. doi request reprint Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease
    Cosimo Prantera
    Gastroenterology Unit, San Camillo Forlanini Hospital, Rome, Italy
    Gastroenterology 142:473-481.e4. 2012
  5. doi request reprint Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol
    C Prantera
    Department of Gastroenterology, Azienda Osp S Camillo Forlanini, Rome, Italy
    Aliment Pharmacol Ther 30:908-18. 2009
  6. pmc Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG
    C Prantera
    Division of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Gut 51:405-9. 2002
  7. ncbi request reprint Mycobacteria and Crohn's disease: the endless story
    C Prantera
    Gastrointestinal Unit, San Camillo Forlanini Hospital, Rome, Italy
    Dig Liver Dis 39:452-4. 2007
  8. pmc Probiotics for Crohn's disease: what have we learned?
    C Prantera
    Division of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, 00149 Roma, Italia
    Gut 55:757-9. 2006
  9. ncbi request reprint Probiotics and Crohn's disease
    C Prantera
    Division of Gastroenterology, S Camillo Forlanini Hospital, Rome, Italy
    Dig Liver Dis 34:S66-7. 2002
  10. ncbi request reprint Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin
    C Prantera
    Operative Unit of Gastroenterology, St Camillo Forlanini Hospital, Rome, Italy
    Aliment Pharmacol Ther 23:1117-25. 2006

Detail Information

Publications18

  1. ncbi request reprint A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
    Cosimo Prantera
    Department of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Inflamm Bowel Dis 11:421-7. 2005
    ..This study had 2 objectives: (1) to evaluate the therapeutic response to MMx in patients with active left-sided disease and (2) to gain additional insights as to how the therapy would compare with topical 5-ASA...
  2. doi request reprint Beclomethasone dipropionate in Crohn's ileitis: a randomised, double-blind trial
    Cosimo Prantera
    Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Dig Liver Dis 43:459-64. 2011
    ..Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects...
  3. doi request reprint Budesonide multi-matrix system formulation for treating ulcerative colitis
    Cosimo Prantera
    Gastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87 00152 Rome, Italy 39 6 3202643 39 6 3202643
    Expert Opin Pharmacother 15:741-3. 2014
    ..Therefore, the effective dosage should be 9 mg also in maintenance, but not for > 4 - 6 months, because a prolonged treatment has showed to increase the rate of side effects. ..
  4. doi request reprint Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease
    Cosimo Prantera
    Gastroenterology Unit, San Camillo Forlanini Hospital, Rome, Italy
    Gastroenterology 142:473-481.e4. 2012
    ..We performed a clinical phase 2 trial to determine whether a gastroresistant formulation of rifaximin (extended intestinal release [EIR]) induced remission in patients with moderately active CD...
  5. doi request reprint Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol
    C Prantera
    Department of Gastroenterology, Azienda Osp S Camillo Forlanini, Rome, Italy
    Aliment Pharmacol Ther 30:908-18. 2009
    ..5-ASA-MMX (1.2 g/tablet) is a 5-aminosalicylic acid formulation, designed for once-daily dosing in the treatment of ulcerative colitis...
  6. pmc Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG
    C Prantera
    Division of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Gut 51:405-9. 2002
    ..The aim of this randomised placebo controlled study was to determine if Lactobacillus GG, given by mouth for one year, could prevent Crohn's recurrent lesions after surgery or to reduce their severity...
  7. ncbi request reprint Mycobacteria and Crohn's disease: the endless story
    C Prantera
    Gastrointestinal Unit, San Camillo Forlanini Hospital, Rome, Italy
    Dig Liver Dis 39:452-4. 2007
  8. pmc Probiotics for Crohn's disease: what have we learned?
    C Prantera
    Division of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, 00149 Roma, Italia
    Gut 55:757-9. 2006
  9. ncbi request reprint Probiotics and Crohn's disease
    C Prantera
    Division of Gastroenterology, S Camillo Forlanini Hospital, Rome, Italy
    Dig Liver Dis 34:S66-7. 2002
    ..Forty-five patients have been randomised to receive Lactobacillus rhamnosus strain GG or placebo for 12 months. The results have shown no differences in endoscopic and clinical remission between the two groups...
  10. ncbi request reprint Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin
    C Prantera
    Operative Unit of Gastroenterology, St Camillo Forlanini Hospital, Rome, Italy
    Aliment Pharmacol Ther 23:1117-25. 2006
    ..Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients...
  11. doi request reprint Antibiotics and probiotics in inflammatory bowel disease: why, when, and how
    Cosimo Prantera
    Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Curr Opin Gastroenterol 25:329-33. 2009
    ..To summarize recent evidence on the role of intestinal bacteria in inflammatory bowel diseases, and of antibiotics and probiotics in their treatment. The implications connected with the use of antibiotics are also examined...
  12. pmc Use of antibiotics in the treatment of Crohn's disease
    Maria Lia Scribano
    Gastroenterology Operative Unit, Azienda Ospedaliera San Camillo Forlanini, 00152 Rome, Italy
    World J Gastroenterol 19:648-53. 2013
    ..Rifaximin, characterized by an excellent safety profile, has provided promising results in inducing remission of CD...
  13. ncbi request reprint Delayed-release Multi Matrix System (MMX) mesalazine in ulcerative colitis: a viewpoint by Cosimo Prantera
    Cosimo Prantera
    Gastroenterology Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Drugs 67:2643-4. 2007
  14. doi request reprint Antibiotics and inflammatory bowel diseases
    Maria Lia Scribano
    Gastroenterology Operative Unit, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy
    Dig Dis 31:379-84. 2013
    ..Since their long-term use is frequently complicated by a high rate of side effects, the use of antibiotics that work locally appears to be promising...
  15. pmc Rifaximin and Crohn's disease
    Cosimo Prantera
    Cosimo Prantera, Maria Lia Scribano, Gastroenterology Operative Unit, Azienda Ospedaliera San Camillo Forlanini, 00152 Rome, Italy
    World J Gastroenterol 19:7487-8. 2013
    ..We also analyze the role of rifaximin against gut bacteria and the clinical situations that could obtain the best results from antibiotics. ..
  16. pmc Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity
    Cosimo Prantera
    Azienda Ospedaliera San Camillo Forlanini, via Monterosi 116, 00191 Rome, Italy
    Therap Adv Gastroenterol 6:137-56. 2013
    ..While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted...
  17. ncbi request reprint Does stapled functional end-to-end anastomosis affect recurrence of Crohn's disease after ileocolonic resection?
    Roberto Tersigni
    Department of Surgical Sciences, General Surgery 1, San Camillo Hospital, Rome, Italy
    Hepatogastroenterology 50:1422-5. 2003
    ..The influence of anastomotic configuration on the incidence of reoperation was evaluated in patients undergoing resection for Crohn's disease...
  18. doi request reprint Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use
    Silvio Danese
    Inflamm Bowel Dis 14:1168-70. 2008